c'mon, im serious... it has to get paid for or else they wouldnt be comping us on it right?? i know they arent getting squat for the EGFR and mutations, so what do you guys think is the deal??
how about that 'tumor-specific' coverage for molecular tests.... is this going to hurt us? Or has it already started to??? this space is getting hard........ thoughts?